» Articles » PMID: 36611907

Pancreatic Islet Cells Response to IFNγ Relies on Their Spatial Location Within an Islet

Overview
Journal Cells
Publisher MDPI
Date 2023 Jan 8
PMID 36611907
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes (T1D) is an auto-immune disease characterized by the progressive destruction of insulin-producing pancreatic beta cells. While beta cells are the target of the immune attack, the other islet endocrine cells, namely the alpha and delta cells, can also be affected by the inflammatory milieu. Here, using a flow cytometry-based strategy, we compared the impact of IFNγ, one of the main cytokines involved in T1D, on the three endocrine cell subsets isolated from C57BL/6 mouse islets. RNA-seq analyses revealed that alpha and delta cells exposed in vitro to IFNγ display a transcriptomic profile very similar to that of beta cells, with an increased expression of inflammation key genes such as MHC class I molecules, the CXCL10 chemokine and the programmed death-ligand 1 (PD-L1), three hallmarks of IFNγ signaling. Interestingly, at low IFNγ concentration, we observed two beta cell populations (responders and non-responders) based on PD-L1 protein expression. Our data indicate that this differential sensitivity relies on the location of the cells within the islet rather than on the existence of two different beta cells subsets. The same findings were corroborated by the in vivo analysis of pancreatic islets from the non-obese diabetic mouse model of T1D, showing more intense PD-L1 staining on endocrine cells close to immune infiltrate. Collectively, our work demonstrates that alpha and delta cells are as sensitive as beta cells to IFNγ, and suggests a gradual diffusion of the cytokine into an islet. These observations provide novel insights into the in situ inflammatory processes occurring in T1D progression.

Citing Articles

HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors.

Watanabe M, Eguchi J, Takamoto A, Kanzaki H, Noda Y, Kagawa S Front Endocrinol (Lausanne). 2024; 15:1439705.

PMID: 39722806 PMC: 11668593. DOI: 10.3389/fendo.2024.1439705.


Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans.

Wreven E, Ruiz de Adana M, Hardiville S, Gmyr V, Kerr-Conte J, Chetboun M Diabetologia. 2024; 67(9):1877-1896.

PMID: 38864887 PMC: 11410908. DOI: 10.1007/s00125-024-06193-6.


Pancreatic β-Cell Identity Change through the Lens of Single-Cell Omics Research.

Leenders F, de Koning E, Carlotti F Int J Mol Sci. 2024; 25(9).

PMID: 38731945 PMC: 11083883. DOI: 10.3390/ijms25094720.

References
1.
Falcone M, Fousteri G . Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne). 2020; 11:569. PMC: 7466754. DOI: 10.3389/fendo.2020.00569. View

2.
Perdigoto A, Deng S, Du K, Kuchroo M, Burkhardt D, Tong A . Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022; 7(17). PMC: 9536276. DOI: 10.1172/jci.insight.156330. View

3.
Eizirik D, Mandrup-Poulsen T . A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia. 2002; 44(12):2115-33. DOI: 10.1007/s001250100021. View

4.
Thomas H, Parker J, Schreiber R, Kay T . IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest. 1998; 102(6):1249-57. PMC: 509108. DOI: 10.1172/JCI2899. View

5.
Guleria I, Bupp M, Dada S, Fife B, Tang Q, Ansari M . Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007; 125(1):16-25. DOI: 10.1016/j.clim.2007.05.013. View